University Health Network
Toronto, Ontario, Canada
54 recruiting
Showing 1–20 of 119 trials
Recruiting
Phase 2Phase 3
Taurine Supplementation in Long COVID
Long COVID
University of Alberta300 enrolled5 locationsNCT06721949
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Genentech, Inc.186 enrolledNCT04910568
Recruiting
Not Applicable
The Fourth Left Atrial Appendage Occlusion Study
Atrial FibrillationStroke, IschemicSystemic Embolism
Hamilton Health Sciences Corporation4,000 enrolled140 locationsNCT05963698
Recruiting
Phase 2
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Cancer
Canadian Cancer Trials Group60 enrolled11 locationsNCT03847649
Recruiting
Phase 2
LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma
Melanoma
Canadian Cancer Trials Group128 enrolled14 locationsNCT06623461
Recruiting
Phase 3
Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer
Advanced Head and Neck Cancer
Canadian Cancer Trials Group196 enrolled9 locationsNCT06641791
Recruiting
Not Applicable
Emotion and Symptom-Focused Engagement Trial for Individuals With Acute Leukemia
Acute Leukemia
Canadian Cancer Trials Group266 enrolled5 locationsNCT04224974
Recruiting
Phase 1Phase 2
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMixed Phenotype Acute Leukemia+2 more
Syndax Pharmaceuticals447 enrolled57 locationsNCT04065399
Recruiting
Phase 2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Non-Hodgkin Lymphoma
Canadian Cancer Trials Group30 enrolled8 locationsNCT05998642
Recruiting
Phase 2
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Endometrial Cancer
Canadian Cancer Trials Group393 enrolled114 locationsNCT05640999
Recruiting
Phase 2
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Mantle Cell Lymphoma
Canadian Cancer Trials Group40 enrolled3 locationsNCT07341191
Recruiting
Phase 1
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Triple-Negative Breast CancerRenal Cell CarcinomaAlveolar Soft Part Sarcoma
Canadian Cancer Trials Group30 enrolled2 locationsNCT07297667
Recruiting
Phase 3
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Clostridium Difficile Infection RecurrenceClostridium DifficileClostridioides Difficile Infection+7 more
Vedanta Biosciences, Inc.852 enrolled215 locationsNCT06237452
Recruiting
Phase 4
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
C3 Glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Swedish Orphan Biovitrum150 enrolledNCT07746895
Recruiting
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
Retinitis PigmentosaInherited Retinal Degeneration
Jaeb Center for Health Research1,500 enrolled36 locationsNCT05589714
Recruiting
Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)
PSC
PSC Partners Seeking a Cure2,000 enrolled18 locationsNCT06297993
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Parkinson's Disease
Hoffmann-La Roche900 enrolled174 locationsNCT07174310
Recruiting
Not Applicable
A Platform Trial for Gram Negative Bloodstream Infections
Gram-negative Bacteremia
Sunnybrook Health Sciences Centre2,500 enrolled39 locationsNCT06537609
Recruiting
Phase 3
SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
Congenital Heart Disease
Subodh Verma410 enrolledNCT06955260
Recruiting
WRAP North America
Venous StenosisVenous Occlusion
Merit Medical Systems, Inc.250 enrolled16 locationsNCT06807099